Other

Neuova, LLC

Cardiopharma, Inc.

Roy A Stimits

Stephan D Glenn

Daniel Tyree Gregory, Jr

Daniel T Gregory

Frank Detlev Goj

Wayne L Whittingham

David P Hause

Daniel Tyree Gregory Jr

Stephan Dale Glenn

Disclosed is a method of manufacturing a cardiovascular fixed-dose combination pharmaceutical dosage form that includes an anti-hypertensive active agent, a cholesterol-lowering active agent, and optionally, an enteric-coated aspirin or platelet inhibitor. The fixed-dose combination is prepared with at least two granulation solutions that are free of citric acid and enhance the aqueous solubility of the cholesterol-lowering agent in fixed-dose combination. The active agents in the resulting dosage form, which is also free of citric acid, have the same strength and release profiles as the same active agents prepared as a single formulation.

Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture

A non-invasive, transcutaneous electrical device stimulates nerves using unpulsed, constant direct current. The device uses a constant, unpulsed direct electric current of low constant voltage and power through air core uninsulated wire coil electrodes. The device includes a switch to open or close the circuit, a fuse that serves as the automatic overload trip voltage level, and two wire coil electrodes of uninsulated wire. The coil electrodes are positioned on the forehead directly superior to the eyes proximal to the supraorbital and supratrochlear nerves and apply a direct current transcutaneously to the forehead.

Transcutaneous neural stimulation device

A method of making a consumable product containing purified embryonatedova (TSO) preferably includes steps of: storing the TSO in an acidic solution; adding a food preservative to the acidic solution to produce a preservative-acid-solution; forming a mixing solution by raising the pH of the preservative-acidic-solution to match the pH of a food substance by titrating the preservative-acidic-solution with an acid neutralizer so that the pH changes at a rate of not more than 1 pH unit per 24 hours, preferably to a pH not higher than 5.0; and producing the consumable product by combining the mixing solution and the food substance while maintaining the temperature of the consumable product between 1 degree Centigrade and 47 degrees Centigrade.

[object Object]

Growing community of inventors

Wilmington, NC, United States of America

Roy A Stimits